Share this post:

“Novartis leaving innovation in antibiotics is unfortunate, as we still need effective replacement antibiotics, and Novartis has a few in development. They are in discussions to divest them, so hopefully there’s a suitable partner to complete their development.” – Jayasree K. Iyer, Executive Director of the Access to Medicine Foundation.

Read Full Article